Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis

Lupus

Volumn 19, Issue 8, 2010, Pages 935-940

  Lanata, C M ^a   Mahmood, T ^b   Fine, D M ^a   Petri, M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ST AGNES HOSPITAL   (United States)

Author keywords

nephritis; renal lupus; systemic lupus erythematosus

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HYDROXYCHLOROQUINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT; MYCOPHENOLIC ACID;

AFRICAN AMERICAN; ARTICLE; BACTERIAL ARTHRITIS; CAUCASIAN; CELLULITIS; CLINICAL ARTICLE; COHORT ANALYSIS; DIABETIC KETOACIDOSIS; DISEASE CLASSIFICATION; DRUG DOSE TITRATION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; HERPES ZOSTER; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY BIOPSY; LEG CRAMP; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; MYALGIA; PNEUMONIA; PRIORITY JOURNAL; PROTEINURIA; REMISSION; RETROSPECTIVE STUDY; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE; ADULT; ANALOGS AND DERIVATIVES; DRUG COMBINATION; DRUG RESISTANCE; LUPUS NEPHRITIS; PROSPECTIVE STUDY; TREATMENT FAILURE; YOUNG ADULT;

ADULT; COHORT STUDIES; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS NEPHRITIS; MYCOPHENOLIC ACID; PROSPECTIVE STUDIES; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TACROLIMUS; TREATMENT FAILURE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77954040157     PISSN: 09612033     EISSN: None     Source Type: Journal    
DOI: 10.1177/0961203310365714     Document Type: Article

References (39)

1. Donadio Jr. JV, Hart GM, Bergstralh EJ, Holley KE Prognostic determinants in lupus nephritis: a long-term clinicopathologic study. Lupus 1995 ; 4: 109-115.
2. Mok CC, Wong RW, Lau CS Lupus nephritis in Southern Chinese patients: clinicopathologic findings and long-term outcome. Am J Kidney Dis 1999 ; 34: 315-323.
3. Korbet SM, Lewis EJ, Schwartz MM, Reichlin M., Evans J., Rohde RD Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group. Am J Kidney Dis 2000 ; 35: 904-914.
4. Mok CC Therapeutic options for resistant lupus nephritis. Semin Arthritis Rheum 2006 ; 3: 71-81.
5. Cross J., Dwomoa A., Andrews P., et al. Mycophenolate mofetil for remission induction in severe lupus nephritis. Nephron Clin Pract 2005 ; 100: c92-100.
6. Ginzler EM, Dooley MA, Aranow C., et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005 ; 353 (21). 2219-2228.
7. Chan TM, Li FK, Tang CS, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000 ; 343: 1156-1162.
8. Kapitsinou PP, Boletis JN, Skopouli FN, Boki KA, Moutsopoulos HM Lupus nephritis: treatment with mycophenolate mofetil. Rheumatology (Oxford) 2004 ; 43: 377-380.
9. Hu W., Liu Z., Chen H., et al. Mycophenolate mofetil vs cyclophosphamide therapy for patients with diffuse proliferative lupus nephritis. Chin Med J (Engl) 2002 ; 115: 705-709.
10. Zhu B., Chen N., Lin Y., et al. Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2007 ; 22: 1933-1942.
11. Glicklich D., Acharya A. Mycophenolate mofetil therapy for lupus nephritis refractory to intravenous cyclophosphamide. Am J Kidney Dis 1998 ; 32: 318-322.
12. Dooley MA, Cosio FG, Nachman PH, et al. Mycophenolate mofetil therapy in lupus nephritis: clinical observations. J Am Soc Nephrol 1999 ; 10: 833-839.
13. Sinclair A., Appel G., Dooley MA, et al. Mycophenolate mofetil as induction and maintenance therapy for lupus nephritis: rationale and protocol for the randomized, controlled Aspreva Lupus Management Study (ALMS). Lupus 2007 ; 16: 972-980.
14. Elyan M., Ballou S. The effectiveness and safety of mycophenolate mofetil in lupus nephritis. Clin Rheumatol 2009 ; 28: 835-840.
15. Lu F., Tu Y., Peng X., et al. A prospective multicentre study of mycophenolate mofetil combined with prednisolone as induction therapy in 213 patients with active lupus nephritis. Lupus 2008 ; 17: 622-629.
16. Mendez R. FK 506 and mycophenolate mofetil in renal transplant recipients: six-month results of a multicenter, randomized dose ranging trial. FK 506 MMF Dose-Ranging Kidney Transplant Study Group. Transplant Proc 1998 ; 30: 1287-1289.
17. Mendez R., Gonwa T., Yang HC, Weinstein S., Jensik S., Steinberg S. A prospective, randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: results at 1 year. Transplantation 2005 ; 80: 303-309.
18. Aksu G., Ozturk C., Kavakli K., Genel F., Kutukculer N. Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clin Rheumatol 2007 ; 26: 366-370.
19. Tse KC, Lam MF, Tang SC, Tang CS, Chan TM A pilot study on tacrolimus treatment in membranous or quiescent lupus nephritis with proteinuria resistant to angiotensin inhibition or blockade. Lupus 2007 ; 16: 46-51.
20. Allison AC, Eugui EM Purine metabolism and immunosuppressive effects of mycophenolate mofetil (MMF). Clin Transplant 1996 ; 10: 77-84.
21. Heemann U., Azuma H., Hamar P., Schmid C., Tilney N., Philipp T. Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allografts. Transpl Immunol 1996 ; 4: 64-67.
22. Scott LJ, McKeage K., Keam SJ, Plosker GL Tacrolimus: a further update of its use in the management of organ transplantation. Drugs 2003 ; 63: 1247-1297.
23. Anderson BE, Marks Jr. JG, Mauger DT Efficacy of tacrolimus ointment in the prevention and treatment of contact dermatitis. Dermatitis 2004 ; 15: 158-159.
24. Entani C., Izumino K., Iida H., et al. Effect of a novel immunosuppressant, FK506, on spontaneous lupus nephritis in MRL/ MpJ-lpr/lpr mice. Nephron 1993 ; 64: 471-475.
25. Maruyama M., Yamasaki Y., Sada K., et al. Good response of membranous lupus nephritis to tacrolimus. Clin Nephrol 2006 ; 65: 276-279.
26. Politt D., Heintz B., Floege J., Mertens PR Tacrolimus-(FK 506) based immunosuppression in severe systemic lupus erythematosus. Clin Nephrol 2004 ; 62: 49-53.
27. Mok CC, Tong KH, To CH, Siu YP, Au TC Tacrolimus for induction therapy of diffuse proliferative lupus nephritis: an open-labeled pilot study. Kidney Int 2005 ; 68: 813-817.
28. Bastian HM, Alarcon GS, Roseman JM, et al. Systemic lupus erythematosus in a multiethnic US cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 2007 ; 46: 683-689.
29. Burroughs TE, Swindle J., Takemoto S., et al. Diabetic complications associated with new-onset diabetes mellitus in renal transplant recipients. Transplantation 2007 ; 83: 1027-1034.
30. Dehghani SM, Nikeghbalian S., Eshraghian A., et al. New-onset diabetes mellitus presenting with diabetic ketoacidosis after pediatric liver transplantation. Pediatr Transplant 2009 ; 13: 536-539.
31. Cho YM, Park KS, Jung HS, Kim YS, Kim SY, Lee HK A case showing complete insulin independence after severe diabetic ketoacidosis associated with tacrolimus treatment. Diabetes Care 2002 ; 25: 1664.
32. Toyonaga T., Kondo T., Miyamura N., et al. Sudden onset of diabetes with ketoacidosis in a patient treated with FK506/tacrolimus. Diabetes Res Clin Pract 2002 ; 56: 13-18.
33. Abbott KC, Bernet VJ, Agodoa LY, Yuan CM Diabetic ketoacidosis and hyperglycemic hyperosmolar syndrome after renal transplantation in the United States. BMC Endocr Disord 2003 ; 3: 1.
34. Neu AM, Furth SL, Case BW, Wise B., Colombani PM, Fivush BA Evaluation of neurotoxicity in pediatric renal transplant recipients treated with tacrolimus (FK506). Clin Transplant 1997 ; 11: 412-414. (Pubitemid 27460436)
35. Perrea DN, Moulakakis KG, Poulakou MV, Vlachos IS, Nikiteas N., Kostakis A. Correlation between lipid abnormalities and immunosuppressive therapy in renal transplant recipients with stable renal function. Int Urol Nephrol 2008 ; 40: 521-527.
36. Anzej S., Bozic M., Antovic A., et al. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thromb Res 2007 ; 120: 39-46.
37. Bertsias G., Boumpas DT Update on the management of lupus nephritis: let the treatment fit the patient. Nat Clin Pract Rheumatol 2008 ; 4: 464-472.
38. Melander C., Sallee M., Trolliet P., et al. Rituximab in severe lupus nephritis: early B-cell depletion affects long-term renal outcome. Clin J Am Soc Nephrol 2009.
39. Boletis JN, Marinaki S., Skalioti C., Lionaki SS, Iniotaki A., Sfikakis PP Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study. Nephrol Dial Transplant 2009 ; 24: 2157-2160.